Literature DB >> 19458009

Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection.

J Judy Chang1, Sunee Sirivichayakul, Anchalee Avihingsanon, Alex J V Thompson, Peter Revill, David Iser, John Slavin, Supranee Buranapraditkun, Pip Marks, Gail Matthews, David A Cooper, Stephen J Kent, Paul U Cameron, Joe Sasadeusz, Paul Desmond, Stephen Locarnini, Gregory J Dore, Kiat Ruxrungtham, Sharon R Lewin.   

Abstract

Hepatitis B virus (HBV)-specific T cells play a key role both in the control of HBV replication and in the pathogenesis of liver disease. Human immunodeficiency virus type 1 (HIV-1) coinfection and the presence or absence of HBV e (precore) antigen (HBeAg) significantly alter the natural history of chronic HBV infection. We examined the HBV-specific T-cell responses in treatment-naïve HBeAg-positive and HBeAg-negative HIV-1-HBV-coinfected (n = 24) and HBV-monoinfected (n = 39) Asian patients. Peripheral blood was stimulated with an overlapping peptide library for the whole HBV genome, and tumor necrosis factor alpha and gamma interferon cytokine expression in CD8+ T cells was measured by intracellular cytokine staining and flow cytometry. There was no difference in the overall magnitude of the HBV-specific T-cell responses, but the quality of the response was significantly impaired in HIV-1-HBV-coinfected patients compared with monoinfected patients. In coinfected patients, HBV-specific T cells rarely produced more than one cytokine and responded to fewer HBV proteins than in monoinfected patients. Overall, the frequency and quality of the HBV-specific T-cell responses increased with a higher CD4+ T-cell count (P = 0.018 and 0.032, respectively). There was no relationship between circulating HBV-specific T cells and liver damage as measured by activity and fibrosis scores, and the HBV-specific T-cell responses were not significantly different in patients with either HBeAg-positive or HBeAg-negative disease. The quality of the HBV-specific T-cell response is impaired in the setting of HIV-1-HBV coinfection and is related to the CD4+ T-cell count.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458009      PMCID: PMC2708644          DOI: 10.1128/JVI.00183-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value.

Authors:  J Ockenga; H L Tillmann; C Trautwein; M Stoll; M P Manns; R E Schmidt
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

2.  The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence.

Authors:  D R Milich; M K Chen; J L Hughes; J E Jones
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

3.  Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

Authors:  J F Colin; D Cazals-Hatem; M A Loriot; M Martinot-Peignoux; B N Pham; A Auperin; C Degott; J P Benhamou; S Erlinger; D Valla; P Marcellin
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

4.  Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha.

Authors:  F Su; R J Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

5.  The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response.

Authors:  J F Schlaak; G Tully; H F Löhr; G Gerken; K H Meyer zum Büschenfelde
Journal:  J Hepatol       Date:  1999-03       Impact factor: 25.083

6.  HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines.

Authors:  J F Schlaak; G Tully; H F Löhr; G Gerken; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

7.  Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex.

Authors:  L A Trimble; J Lieberman
Journal:  Blood       Date:  1998-01-15       Impact factor: 22.113

8.  Survival in patients with HIV infection and viral hepatitis B or C: a cohort study.

Authors:  Maurizio Bonacini; Stan Louie; Natalie Bzowej; Amy Rock Wohl
Journal:  AIDS       Date:  2004-10-21       Impact factor: 4.177

9.  The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1.

Authors:  Arthur Y Kim; Georg M Lauer; Kei Ouchi; Marylyn M Addo; Michaela Lucas; Julian Schulze Zur Wiesch; Joerg Timm; Melinda Boczanowski; Jared E Duncan; Alysse G Wurcel; Deborah Casson; Raymond T Chung; Rika Draenert; Paul Klenerman; Bruce D Walker
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

10.  CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity.

Authors:  C Kurts; F R Carbone; M Barnden; E Blanas; J Allison; W R Heath; J F Miller
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

View more
  15 in total

Review 1.  Insights into human immunodeficiency virus-hepatitis B virus co-infection in India.

Authors:  Runu Chakravarty; Ananya Pal
Journal:  World J Virol       Date:  2015-08-12

Review 2.  HBV and HIV co-infection: Impact on liver pathobiology and therapeutic approaches.

Authors:  Mohammad Khalid Parvez
Journal:  World J Hepatol       Date:  2015-01-27

3.  Predictors of loss of hepatitis B surface antigen in HIV-infected patients.

Authors:  George Psevdos; Jong Hun Kim; Jin S Suh; Victoria Lee Sharp
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

4.  No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.

Authors:  Megan Crane; Sunee Sirivichayakul; J Judy Chang; Anchalee Avihingsanon; Sasiwimol Ubolyam; Supranee Buranapraditkun; Pattarawat Thantiworasit; Fiona Wightman; Stephen Locarnini; Gail Matthews; Gregory J Dore; Kiat Ruxrungtham; Sharon R Lewin
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

Review 5.  Screening and diagnosis of HBV in low-income and middle-income countries.

Authors:  Jean-Pierre Allain; Ohene Opare-Sem
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

Review 6.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

7.  Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients.

Authors:  Christian A Engell; Vinh Philip Pham; Robert S Holzman; Judith A Aberg
Journal:  ISRN Gastroenterol       Date:  2011-06-13

8.  Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART.

Authors:  Jennifer Audsley; Eric C Seaberg; Joe Sasadeusz; Gail V Matthews; Anchalee Avihingsanon; Kiat Ruxrungtham; Kit Fairley; Robert Finlayson; Hyon S Hwang; Margaret Littlejohn; Stephen Locarnini; Gregory J Dore; Chloe L Thio; Sharon R Lewin
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

9.  HIV/HBV Co-Infections: Epidemiology, Natural History, and Treatment: A Review Article.

Authors:  R Ranjbar; A Davari; M Izadi; N Jonaidi; S M Alavian
Journal:  Iran Red Crescent Med J       Date:  2011-12-01       Impact factor: 0.611

10.  Hepatitis B virus (HBV)-specific T-cell responses to recombinant HBV core protein in patients with normal liver function and co-infected with chronic HBV and human immunodeficiency virus 1 (HIV-1).

Authors:  Xin Zhang; Hanqian Xing; Xia Feng; Haiping Zhang; Yi Wang; Huiping Yan
Journal:  Virol J       Date:  2013-07-12       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.